AstraZeneca is the biggest drugmaker in Britain and its £193 billion ($253 billion) market capitalization tops the London Stock Exchange.

Under the model, set to start next year, the CMS will negotiate lower prices for Medicaid programs linked to those paid in ...

Future weight loss drugs will also be made available at $149 a month. Other drugs made by the two companies will also be offered at the lower, most-favored-nations price for Medicaid and Trump Rx.

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

Pharma’s push into direct-to-patient sales is reshaping the front end of drug distribution, but wholesalers like Cencora, McKesson, and Cardinal Health remain indispensable as the backbone of the ...

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...

Eli Lilly expanded its AI drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune ...

Drugmakers feel empowered to resist foreign price controls — confident that the Trump administration will have their backs.

The Trump administration on Thursday announced a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to certain Medicare ...

Novo Nordisk and Eli Lilly said they've agreed to sell their blockbuster drugs Wegovy and Zepbound at a discount.

WASHINGTON (AP) — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand ...

Presented by the Coalition to Strengthen America’s Healthcare — State Medicaid programs that choose to participate in the model will be able to purchase drugs included in the pilot at prices ...